Abstract

A REVIEW ON VALIDATION AND DEVELOPMENT OF STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF SAFINAMIDE

Wagh Mohit P.*, Dr. Parjane Smita A. and Prof. Bhosale Mayur S.

ABSTRACT

(S)-2-((4-((3-Fluorobenzyl)oxy benzyl amino) procainamide methanesulfonate is that the IUPAC name for safinamide mesylate. This formulation is recently created and employed in the treatment of Parkinson’s illness. Safinamide is that the supplement of carbidopa associated L-dopa and this is often a mono-amino enzyme (MOA-B) matter. Safinamide mesylate may be a 2nd generation medication agent that has the medical specialty properties having interest of neurodegenerative disorder like palladium. Safinamide area unit moniterized by RP-HPLC, HPLC through the strategy development & validation method. Palladium is characterised deficiency of Dopastat. Safinamide (Xadago®) is associate orally active, selective, reversible amine oxidase-B matter with each dopaminergic and non-dopaminergic (glutamatergic) properties.

Keywords: Parkinson’s disease, safinamide, RP-HPLC.